Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management

作者: Eckart Haneke

DOI: 10.2147/PTT.S126281

关键词: Red lunulaeHyponychiumNail (anatomy)ParonychiaSurgerySubungual hyperkeratosisLeukonychiaDermatologyPsoriasisMedicineOnycholysis

摘要: Psoriasis is the skin disease that most frequently affects nails. Depending on very nail structure involved, different clinical alterations can be observed. Irritation of apical matrix results in psoriatic pits, mid-matrix involvement may cause leukonychia, whole affection lead to red lunulae or severe dystrophy, bed salmon spots, subungual hyperkeratosis, and splinter hemorrhages, psoriasis distal hyponychium causes onycholysis whereas proximal fold paronychia. The more extensive involvement, destruction. Pustular seen as yellow spots under or, case acrodermatitis continua suppurativa, an insidious progressive loss organ. Nail has a impact quality life interfere with professional other activities. Management includes patient counseling, avoidance stress strain apparatus, types treatment. Topical therapy tried but rarely sufficiently efficient. Perilesional injections corticosteroids methotrexate are often beneficial painful cannot applied many All systemic treatments clearing widespread lesions usually also clear lesions. Recently, biologicals were introduced into treatment found effective. However, their use restricted cases due high cost potential adverse effects.

参考文章(114)
Khawer Saleem, Waqar Azim, Treatment of nail psoriasis with a modified regimen of steroid injections. Jcpsp-journal of The College of Physicians and Surgeons Pakistan. ,vol. 18, pp. 78- 81 ,(2008)
Uwe Wollina, Gesina Hansel, André Koch, Jaqueline Schönlebe, Erich Köstler, Gunter Haroske, Tumor Necrosis Factor-α Inhibitor-Induced Psoriasis or Psoriasiform Exanthemata American Journal of Clinical Dermatology. ,vol. 9, pp. 1- 14 ,(2008) , 10.2165/00128071-200809010-00001
C. De Simone, A. Maiorino, F. Tassone, M. D’Agostino, G. Caldarola, Tacrolimus 0.1% ointment in nail psoriasis: a randomized controlled open-label study. Journal of The European Academy of Dermatology and Venereology. ,vol. 27, pp. 1003- 1006 ,(2013) , 10.1111/J.1468-3083.2012.04642.X
K. Reich, J.-P. Ortonne, A.B. Gottlieb, I.J. Terpstra, G. Coteur, C. Tasset, P. Mease, Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension British Journal of Dermatology. ,vol. 167, pp. 180- 190 ,(2012) , 10.1111/J.1365-2133.2012.10941.X
Magalys Vitiello, Antonella Tosti, Adriana Abuchar, Martin Zaiac, Francisco A. Kerdel, Ustekinumab for the treatment of nail psoriasis in heavily treated psoriatic patients International Journal of Dermatology. ,vol. 52, pp. 358- 362 ,(2013) , 10.1111/J.1365-4632.2011.05320.X
C Fabroni, A Gori, M Troiano, F Prignano, T Lotti, Infliximab efficacy in nail psoriasis. A retrospective study in 48 patients. Journal of The European Academy of Dermatology and Venereology. ,vol. 25, pp. 549- 553 ,(2011) , 10.1111/J.1468-3083.2010.03826.X
M Snchez Regaa, G Mrquez Balbs, P Umbert Millet, Nail psoriasis: a combined treatment with 8% clobetasol nail lacquer and tacalcitol ointment. Journal of The European Academy of Dermatology and Venereology. ,vol. 22, pp. 963- 969 ,(2008) , 10.1111/J.1468-3083.2008.02679.X
J.P. Ortonne, C. Paul, E. Berardesca, V. Marino, G. Gallo, Y. Brault, J.M. Germain, A 24‐week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis British Journal of Dermatology. ,vol. 168, pp. 1080- 1087 ,(2013) , 10.1111/BJD.12060
Anna Christa Q de Vries, Nathalie A Bogaards, Lotty Hooft, Marieke Velema, Marcel Pasch, Mark Lebwohl, Phyllis I Spuls, Interventions for nail psoriasis Cochrane Database of Systematic Reviews. ,vol. 2013, ,(2013) , 10.1002/14651858.CD007633.PUB2